Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Nodurft

Gastroenterology La Jolla, CA Medical Doctor

NPI 1265540843 CMS profile 284663

10666 N Torrey Pines Rd, La Jolla, CA 92037

Open in the dashboard

General payments

$6,349

320 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Nodurft of La Jolla, CA is reported in the CMS Open Payments database as having received $6,349 across 320 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,353 63
2024 General $1,471 71
2023 General $1,125 53
2022 General $894 43
2021 General $457 21
2020 General $343 17
2019 General $705 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Nodurft
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Richard Nodurft were reported at $1,353. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Richard Nodurft Gastroenterology median Middle half National median
2019 $705 $417 $126–$1,100 $163
2020 $343 $224 $74–$624 $114
2021 $457 $352 $106–$1,054 $132
2022 $894 $448 $129–$1,270 $149
2023 $1,125 $533 $150–$1,390 $160
2024 $1,471 $605 $160–$1,606 $164
2025 $1,353 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,015 100 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,126 53 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $436 21 payments
  4. Genzyme Corporation $335 11 payments
  5. Ardelyx, Inc. $331 19 payments
  6. Janssen Biotech, Inc. $289 15 payments
  7. Regeneron Healthcare Solutions, Inc. $276 10 payments
  8. Pfizer Inc. $274 14 payments
  9. Celgene Corporation $200 13 payments
  10. Lilly USA, LLC $172 6 payments
  11. Other $895 58 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,349 320 payments
Products named General payments · program years 2019–2025
  1. ENTYVIO $874 35 payments
  2. RINVOQ $831 42 payments
  3. SKYRIZI Immunology $655 33 payments
  4. HUMIRA $586 28 payments
  5. LINZESS $448 32 payments
  6. XIFAXAN $408 19 payments
  7. DUPIXENT Immunology $335 11 payments
  8. IBSRELA $331 19 payments
  9. DUPIXENT Inflammation And Immunology $257 9 payments
  10. SKYRIZI Immunology $255 13 payments
  11. Other $2,483 135 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,004

Median for Gastroenterology: 569

Drug cost

$673,161

Median for Gastroenterology: $104,976

Branded share of claims

43.8%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 15 $388,733
Rinvoq Upadacitinib Brand 18 $121,914
Linzess Linaclotide Brand 70 $77,477
Creon Lipase/Protease/Amylase Brand 15 $24,083
Dexlansoprazole Dr Dexlansoprazole Brand 28 $14,027
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 210 $13,960
Balsalazide Disodium Generic 34 $7,209
Mesalamine Generic 13 $6,285
Budesonide Generic 11 $5,083
Pantoprazole Sodium Generic 184 $2,915

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$168,517

Medicare's payments for the services billed

Medicare patients

698

Average age 75

Services billed

2,571

373 women, 325 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 42%
Ischemic heart disease 28%
Diabetes 25%
Chronic kidney disease 24%
Depression 23%
Atrial fibrillation 21%
Osteoporosis 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $243
$243 — —
DUPIXENT
  • GENZYME CORPORATION $143
  • Regeneron Healthcare Solutions, Inc. $90
$233 — —
RINVOQ
  • AbbVie, Inc. $170
$170 18 —
IBSRELA
  • Ardelyx, Inc. $150
$150 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $104
$104 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

320 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record